Astex Pharmaceuticals

OrganisationROR

Trials

NCT06802146
Collaborator, Early phase 1, Recruiting, 108 people, 31 Jan 2025
NCT06191978
Collaborator, Phase 1, Recruiting, 40 people, 5 Jan 2024
NCT05835011
Phase 2, Terminated, 2 people, 28 Apr 2023
NCT05456269
Collaborator, Phase 1, Withdrawn, 0 people, 13 Jul 2022
NCT05360160
Collaborator, Phase 1/2, Recruiting, 43 people, 4 May 2022
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Collaborator, Phase 2, Active, not recruiting, 39 people, 17 Aug 2021
NCT04655755
Collaborator, Phase 1/2, Active, not recruiting, 52 people, 7 Dec 2020
NCT04155580
Phase 1, Terminated, 68 people, 7 Nov 2019
NCT04061421
Collaborator, Phase 1/2, Recruiting, 94 people, 19 Aug 2019
NCT03913455
Collaborator, Phase 2, Completed, 24 people, 12 Apr 2019
NCT03875287
Collaborator, Phase 1, Active, not recruiting, 35 people, 14 Mar 2019
NCT03813186
Phase 1, Completed, 18 people, 23 Jan 2019
NCT03306264
Phase 3, Completed, 227 people, 11 Oct 2017
NCT03019003
Collaborator, Phase 1, Completed, 13 people, 12 Jan 2017
NCT02103478
Phase 1/2, Completed, 130 people, 4 Apr 2014
NCT01696032
Phase 2, Completed, 120 people, 28 Sept 2012
NCT01685268
Phase 1/2, Completed, 49 people, 14 Sept 2012
NCT00881166
Phase 1, Completed, 101 people, 15 Apr 2009
NCT00571662
Collaborator, Phase 2, Completed, 76 people, 12 Dec 2007
NCT00506922
Collaborator, Phase 1/2, Completed, 150 people, 25 Jul 2007